We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
+6.51%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$904M
AUM Growth
+$341M
Cap. Flow
+$316M
Cap. Flow %
34.95%
Top 10 Hldgs %
51.85%
Holding
63
New
24
Increased
11
Reduced
9
Closed
12

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$48.9M
2
UTHR icon
United Therapeutics
UTHR
+$25.4M
3
BIIB icon
Biogen
BIIB
+$24.9M
4
ARVN icon
Arvinas
ARVN
+$24.3M
5
JBIO
Jade Biosciences
JBIO
+$19.9M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$35.5M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$27.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$21.8M
4
BNTX icon
BioNTech
BNTX
+$18.2M
5
ETNB
89bio
ETNB
+$18.2M

Sector Composition

Rank Sector Weight
1 Healthcare 82.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$82.9M 9.18%
+1,000,000
New +$79.8M
IDYA icon
2
IDEAYA Biosciences
IDYA
$3.46B
$70.3M 7.78%
3,345,000
-155,000
-4% -$2.97M
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$64M 7.08%
1,200,000
– –
RVMD icon
4
Revolution Medicines
RVMD
$39.8B
$62.5M 6.92%
1,700,000
+100,000
+6% +$3.84M
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$15.9B
$47.8M 5.28%
+450,000
New +$48.9M
IRON icon
6
Disc Medicine
IRON
$2.86B
$37.1M 4.1%
700,000
+305,658
+78% +$14.4M
RNAM
7
DELISTED
Avidity Biosciences
RNAM
$27M 2.99%
950,000
+600,000
+171% +$17.9M
KROS icon
8
Keros Therapeutics
KROS
$204M
$26.7M 2.95%
2,000,000
– –
TEVA icon
9
CALL
Teva Pharmaceuticals
TEVA
$36.2B
$25.1M 2.78%
+1,500,000
New +$24.2M
BIIB icon
10
Biogen
BIIB
$29.7B
$25.1M 2.78%
+200,000
New +$24.9M
UTHR icon
11
United Therapeutics
UTHR
$26.4B
$24.4M 2.7%
+85,000
New +$25.4M
ARVN icon
12
Arvinas
ARVN
$534M
$24.3M 2.69%
+3,300,000
New +$24.3M
JANX icon
13
Janux Therapeutics
JANX
$962M
$23.1M 2.56%
1,000,000
-650,000
-39% -$17.1M
OCUL icon
14
Ocular Therapeutix
OCUL
$1.88B
$20.4M 2.26%
2,200,000
-100,000
-4% -$783K
ERAS icon
15
Erasca
ERAS
$6.63B
$19.1M 2.11%
15,000,000
+2,000,000
+15% +$2.68M
NBIX icon
16
Neurocrine Biosciences
NBIX
$17.8B
$18.9M 2.09%
+150,000
New +$17.2M
DYN icon
17
Dyne Therapeutics
DYN
$4.16B
$18.1M 2%
1,900,000
+1,400,000
+280% +$15.4M
IMCR icon
18
Immunocore
IMCR
$1.76B
$18M 2%
+575,000
New +$17.9M
GPCR icon
19
Structure Therapeutics
GPCR
$3.49B
$17.6M 1.95%
850,000
+425,000
+100% +$9.34M
APLS
20
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$17.3M 1.92%
+1,000,000
New +$18.5M
MDGL icon
21
Madrigal Pharmaceuticals
MDGL
$12.8B
$15.1M 1.67%
+50,000
New +$14.9M
DSGN icon
22
Design Therapeutics
DSGN
$747M
$14.2M 1.57%
4,217,627
– –
KRYS icon
23
Krystal Biotech
KRYS
$10.1B
$13.7M 1.52%
+100,000
New +$14.7M
OLMA icon
24
Olema Pharmaceuticals
OLMA
$1.08B
$13.7M 1.51%
3,208,875
– –
CLDX icon
25
Celldex Therapeutics
CLDX
$2.8B
$12.2M 1.35%
+600,000
New +$11.7M
1
2 3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q2 2025 Portfolio in Review

As of Q2 2025, Logos Global Management held 63 positions worth $904M, up 61% from $563M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Logos Global Management deployed $316M of net new capital in Q2 2025, opening 24 new positions and adding to 11 existing holdings. Its largest new stake was Jazz Pharmaceuticals: 450,000 shares worth $47.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $17.1M trimmed.

  • Logos Global Management's largest Q2 2025 buy was Jazz Pharmaceuticals: 450,000 shares worth $47.8M.
  • Logos Global Management added most to Jade Biosciences in Q2 2025, an estimated $19.9M increase.
  • Logos Global Management's biggest Q2 2025 reduction was Janux Therapeutics, cutting an estimated $17.1M.
  • Logos Global Management fully exited Nuvalent in Q2 2025, selling an estimated $35.5M.
  • Logos Global Management's ten largest holdings make up 52% of its $904M portfolio in Q2 2025.
  • Logos Global Management opened 24 new positions and closed 12 in Q2 2025.
  • Logos Global Management's portfolio value rose 61% quarter-over-quarter to $904M.

Based on Logos Global Management's 13F filing for Q2 2025, filed 14 Aug 2025.